Researchers uncover why typically normal protein drives prostate cancer

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

Af­ter her con­tro­ver­sial nom­i­na­tion by Alex Den­ner to Bio­gen’s board, Su­san Langer was elect­ed this week with few­er votes than any oth­er mem­ber of the

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes